These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 31721165)

  • 41. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.
    Zucchi A; Costantini E; Scroppo FI; Silvani M; Kopa Z; Illiano E; Petrillo MG; Cari L; Nocentini G
    Andrology; 2019 Nov; 7(6):804-817. PubMed ID: 31350821
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [How effective are PDE-5 inhibitors?].
    Jünemann KP
    Urologe A; 2003 Apr; 42(4):553-8. PubMed ID: 12715127
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
    Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
    Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phosphodiesterase-5 inhibitors: future perspectives.
    Konstantinos G; Petros P
    Curr Pharm Des; 2009; 15(30):3540-51. PubMed ID: 19860699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Gresser U; Gleiter CH
    Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.
    Kukreja RC; Salloum FN; Das A; Koka S; Ockaili RA; Xi L
    Exp Clin Cardiol; 2011; 16(4):e30-5. PubMed ID: 22131856
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of phosphodiesterase type 5 inhibitors in assistive living and home care settings.
    Iannino-Renz R; Mager D
    Appl Nurs Res; 2015 Aug; 28(3):251-3. PubMed ID: 26060141
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses.
    Mostafa T
    J Sex Med; 2008 Nov; 5(11):2502-18. PubMed ID: 18761597
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].
    Porst H
    Urologe A; 2004 Jul; 43(7):820-8. PubMed ID: 15197447
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis.
    Abbasi B; Shaw NM; Lui JL; Hakam N; Nabavizadeh B; Breyer BN
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5721. PubMed ID: 37909414
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Experience of using three phosphodiesterase type 5 inhibitors in the same period for the treatment of erectile dysfunction].
    Zhang SX; Gao P
    Zhonghua Nan Ke Xue; 2007 Mar; 13(3):226-8. PubMed ID: 17393785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
    Montorsi F; Corbin J; Phillips S
    J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
    Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
    Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
    Wright PJ
    Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular effects of phosphodiesterase 5 inhibitors.
    Reffelmann T; Kloner RA
    Curr Pharm Des; 2006; 12(27):3485-94. PubMed ID: 17017941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Off-Target Effect of Sildenafil on Postsurgical Erectile Dysfunction: Alternate Pathways and Localized Delivery System.
    Salmasi A; Lee GT; Patel N; Goyal R; Dinizo M; Kwon YS; Modi PK; Faiena I; Kim HJ; Lee N; Hannan JL; Kohn J; Kim IY
    J Sex Med; 2016 Dec; 13(12):1834-1843. PubMed ID: 27843073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.